The effects of propranolol (DL-propranolol) and Dpropranolol on thyroid hormone metabolism were studied in six euthyroid volunteers receiving L-thyroxine (T4) and six hypothyroid patients receiving T4 replacement. D-propranolol as well as propranolol decreased Ltriiodothyronine (T3) concentrations and the ratio of T3 to T4 in the euthyroid subjects, and D-propranolol decreased these variables in the subjects with hypothyroidism (propranolol was not given to this group).
Introduction
Decreased plasma concentrations of L-triiodothyronine (T3) after treatment with propranolol (DL-propranolol) have been well documented in euthyroid subjects, hyperthyroid patients, and hypothyroid patients receiving L-thyronine (T4) replacement. '-9 Propranolol inhibits the conversion of T4 to T3 by peripheral tissues,4 5but the mechanism by which it exerts this effect is not clear.
We recently showed that both L-propranolol, the betablocking isomer, and D-propranolol, which is devoid of betablocking activity, directly inhibit production of T3 from T4 in vitro in an isolated rat renal tubule system.6 These in-vitro investigations suggested that this inhibition of conversion by propranolol is not related to the drug's beta-blocking action but due to its "membrane-stabilising activity."6 The concentrations of propranolol used, however, were high, and the relevance of these in-vitro studies to use of the drug in vivo was not clear. Indeed, the membrane-stabilising actions of propranolol have been assumed to be unimportant at the usual therapeutic doses. 7 We describe here investigations designed to determine whether D-propranolol also inhibits the conversion of T4 to T3 in vivo, thus showing whether the inhibition of this conversion depends on beta-adrenergic blockade.
Subjects and methods
Studies were carried out on six normal, euthyroid volunteers (three women and three men) and six middle-aged hypothyroid subjects (one woman and five men) receiving T4 replacement.
Blood samples were taken on day 1 from the six euthyroid volunteers, who then began taking 200 ,ug of T4 daily throughout the study, which lasted 56 days. On day 14 blood samples were taken and the subjects in group A (two women, one man) began taking propranolol (Inderal) 80 mg twice daily while those in group B (one woman, two men) began taking D-propranolol 80 mg twice daily. Blood samples were taken again on day 28, when the subjects stopped taking the drugs. On day 42 blood samples were taken and the groups began two weeks' treatment with the other drug-that is, group A began taking D-propranolol and group B propranolol, both 80 mg twice daily. Blood samples were obtained again on day 56, when the subjects stopped taking the drugs and T4.
The six patients who were receiving T4 replacement for hypothyroidism took D-propranolol 80 mg twice daily for 14 days. Blood samples were taken and pulse rate and blood pressure measured before and after the course of tablets.
T3, T4, and thyroid-stimulating hormone (TSH) radioimmunoassays were performed on the plasma from each subject, and all samples were assayed together in each radioimmunoassay. T3 was measured as described,8 and T4 and TSH radioimmunoassays were performed using commercially available kits (Radiochemical Centre, Amersham, England; MRC 68/38 TSH standard).
Paired Student's t tests were used for statistical evaluation of the results.
Results
Euthyroid volunteers receiving T4-Plasma T3 concentrations were significantly decreased after two weeks' treatment with propranolol (p < 0 01) and D-propranolol (p < 0 05) (table I). Circulating T4 concentrations were not significantly changed after treatment with either drug. TSH concentrations were suppressed throughout the study. The ratio of T3 to T4 decreased significantly and to a similar extent during both periods of treatment (p < 0-02 for both drugs).
Patients with hypothyroidism receiving T4 showed no change in pulse rate or blood pressure after two weeks' treatment with Dpropr-tnolol (table II) . Plasma concentrations of T3 were significantly decreased (p <0 02) but those of T4 remained unchanged after the treatment (figure). The ratio of T3 to T4 was significantly depressed after treatment (p < 0 02). TSH concentrations did not change significantly. 1 nmol/l 77-7 ng/100 ml.
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Discussion
Propranolol has been widely used for almost a decade to provide symptomatic relief of thyrotoxicosis.9 Its beneficial effects are largely attributed to beta-adrenergic blockade. Recently, propranolol has been shown to affect the concentration of T3 in the circulation,' 4 10 although it has no effect on thyroid hormone secretion.11 The decrease in T3 concentration is due to inhibition of the conversion of T4 to T3 by the peripheral tissues,4 5 and this reduced conversion during propranolol treatment may explain some of the beneficial effects of propranolol in thyrotoxicosis.1 We have shown a decrease in T3 concentrations and in the ratio of T3 to T4 during propranolol treatment, confirming these reports.
In-vitro studies" showed that both D-and L-isomers of propranolol inhibit formation of T3 from T4 by isolated rat renal tubules, indicating that the inhibition of the deiodination of T4 to T3 by propranolol is probably not due to the drug's beta-blocking action. Furthermore, the effect of both isomers was reproducible by quinidine, showing that it was a "membrane-stabilising" or "quinidine-like" effect.
The present studies show that T3 concentrations and the ratio of T3 to T4 fell when D-propranolol was given to normal subjects receiving T4 and hypothyroid subjects receiving T4 replacement. Thus the in-vitro data are relevant to man and propranolol decreases conversion of T4 to T3 by an effect that is independent of beta-adrenergic blockade and is probably related to the drug's membrane-stabilising activity. The lack of effect of D-propranolol on pulse and blood pressure together with a chemical analysis by the manufacturer showed that the D-propranolol tablets did not contain any appreciable amount of L-propranolol. That the effect occurred in both groups studied (normal subjects with suppressed TSH secretion and hypothyroid subjects receiving T4 replacement) indicates that it was not due to altered secretion from the thyroid gland. In-vitro studies showed that it was not due to a change in the stability of T3, and also that the preparation of D-propranolol used was devoid of beta-adrenergic blocking activity.,
The mechanism by which the membrane-stabilising actions of propranolol affect the conversion of T4 to T3 is not clear. Recent studies, however, show that the outer ring deiodinase that effects the conversion is associated with the plasma membrane,12 3l raising the possibility that drugs that act on the membrane directly affect the activity of the enzyme. Alternatively, the effect might be mediated by changes in ion fluxes or other membrane-dependent effects.
We think that this is the first time that appreciable membranestabilising actions of propranolol have been observed in man at low therapeutic doses. It does not necessarily follow that the major mechanism of the beneficial effect of propranolol in man is its effect on the conversion of T4 to T3 or that D-propranolol would be as effective as the beta-blocking L-isomer in symptomatically treating this condition. Clearly, though, low doses of the D-isomer of propranolol can have important biological effects.
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